drugset / Trial / NCT07418177
Study in Human iPSCs-derived RPE Cells Transplantation for Late-Stage AMD
Phase 1/2
Not yet recruiting
9 enrolled
The First Affiliated Hospital with Nanjing Medical University
NaSingle-groupOpen-labelTreatment
Summary
Phase I Study of the Safety and Preliminary Efficacy of Human induced pluripotent stem cells-derived Retinal Pigment Epithelial (HiPSC-RPE) Cells Subretinal Transplantation in Late-Stage Age-Related Macular Degeneration(AMD) Patients
Timeline
- Start
- 2026-02-10
- Primary completion
- 2028-06-01
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HiPSC-RPE cells | Cell therapy | — | Other |
| Background | Erlotinib | Small molecule | 150 mg | Oral |
| Background | Prednisone | Other / unclassified | 30 mg | — |